Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients

Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients
Tesaro will present three abstracts with results from the ENGOT-OV16/NOVA trial evaluating the effectiveness of Zejula (niraparib) in patients with recurrent ovarian cancer at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The company will also host an investor and analyst briefing to provide a business overview and an update on its product pipeline at the conference, being held June 2-6 in Chicago. The investor briefing will be recorded live and will be available online for 30 days on Tesaro’s website. In March this year, the U.S. Food and Drug Administration (FDA) approved Zejula as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. “We’re excited to see presentations of additional data from the landmark ENGOT-OV16/NOVA trial presented at this year’s ASCO Annual Meeting,” Mary Lynne Hedley, PhD, the president and chief operating officer of Tesaro, said in a press release. “We also look forward to sharing initial data from the TOPACIO trial of niraparib plus pembrolizumab, as well as data from the Phase 1 trial of TSR-042, our anti-PD-1 antibody, at our ASCO investor briefing.” Zejula is a PARP inhibitor and promotes cancer cell death by preventing proper repair of DNA damage. It has emerged as a promising therapy for ovarian cancer patients with low frequency of severe side effects. The Phase 3 ENGOT-OV16/NOVA trial (
Subscribe or to access all post and page content.